Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hershey, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Langhorne, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lubbock, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Temple, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Falls Church, VA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Newport News, VA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
509
mi
from
Graz,
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
509
mi
from
Graz,
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Washington,
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Call for Information (Investigational Site 0629)
mi
from
Harrison, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Call for Information (Investigational Site 0629)
mi
from
Harrison, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Rockville Centre, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
Ochsner Medical Center
mi
from
New Orleans, LA
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
Massachusetts General Hospital
mi
from
Boston, MA
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
Jefferson Medical College of Thomas Jefferson University
mi
from
Philadelphia, PA
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
Jefferson Medical College of Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
Copenhagen University Hospital at Herlev
mi
from
Copenhagen,
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
Copenhagen University Hospital at Herlev
mi
from
Copenhagen,
Click here to add this to my saved trials
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated:  1/15/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions
Status: Enrolling
Updated: 1/15/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Montebello, CA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Montebello, CA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Mountain View, CA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Mountain View, CA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Galesburg, IL
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Galesburg, IL
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Overland Park, KA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Wichita, KA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Great Falls, MT
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Great Falls, MT
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cherry Hill, NJ
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Staten Island, NY
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bismarck, ND
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bethlehem, PA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lacey, WA
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lacey, WA
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Mount Sinai Hospital
mi
from
New York, NY
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Pilot Study of Acupuncture Treatment for Dysphagia
Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer Patients: A Pilot Randomized Control Trial
Status: Enrolling
Updated:  1/16/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Pilot Study of Acupuncture Treatment for Dysphagia
Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer Patients: A Pilot Randomized Control Trial
Status: Enrolling
Updated: 1/16/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  1/16/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 1/16/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials